Convelo Therapeutics, Inc.
Convelo is from a Latin word meaning "to wrap around". Convelo Therapeutics is committed to developing medicines to regenerate myelin around nerve cells and restoring function to patients with neurological disorders.
At Convelo Therapeutics, we strive for scientific excellence regardless of how great the challenge. The force that inspires and drives us is our commitment to providing innovative and life-changing medicines for patients and their families.
Convelo Therapeutics was founded in 2016 by Case Western Reserve University School of Medicine professors Paul Tesar, PhD and Drew Adams, PhD to translate discoveries from their laboratories into medicines for critically ill patients. They were joined by biotech veteran Steven Landau, MD.
In 2018, Convelo Therapeutics announced the closing of $7.8M in funding led by Cleveland Convelo Holdings, LLC. Concurrently, Convelo Therapeutics announced that biotech pioneer Derrick Rossi, PhD was appointed as President and CEO.